Twist Bioscience Co. (NASDAQ:TWST) Receives $46.63 Average Target Price from Analysts

Shares of Twist Bioscience Co. (NASDAQ:TWST) have earned an average rating of “Buy” from the eight research firms that are currently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $48.50.

A number of brokerages recently weighed in on TWST. TD Cowen increased their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Evercore ISI raised their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Scotiabank upped their price objective on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research note on Monday, May 6th. Barclays increased their price objective on Twist Bioscience from $45.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price on the stock.

Twist Bioscience Stock Performance

TWST opened at $49.28 on Friday. The stock has a market capitalization of $2.87 billion, a P/E ratio of -14.67 and a beta of 1.78. Twist Bioscience has a one year low of $14.42 and a one year high of $55.26. The business’s 50-day simple moving average is $43.84 and its 200-day simple moving average is $38.27.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The company had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.06) earnings per share. On average, equities research analysts forecast that Twist Bioscience will post -3.08 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, insider William Banyai sold 798 shares of the stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $29,629.74. Following the completion of the transaction, the insider now owns 345,188 shares in the company, valued at $12,816,830.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Emily M. Leproust sold 4,163 shares of the business’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $154,572.19. Following the sale, the chief executive officer now directly owns 509,986 shares in the company, valued at approximately $18,935,780.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Banyai sold 798 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now directly owns 345,188 shares in the company, valued at approximately $12,816,830.44. The disclosure for this sale can be found here. Insiders have sold a total of 19,426 shares of company stock worth $777,966 over the last three months. 3.92% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the stock. Castleark Management LLC lifted its position in shares of Twist Bioscience by 11.8% in the first quarter. Castleark Management LLC now owns 146,630 shares of the company’s stock valued at $5,031,000 after acquiring an additional 15,470 shares in the last quarter. Bayesian Capital Management LP boosted its stake in shares of Twist Bioscience by 42.7% during the 1st quarter. Bayesian Capital Management LP now owns 14,546 shares of the company’s stock worth $499,000 after purchasing an additional 4,352 shares during the last quarter. Silvercrest Asset Management Group LLC boosted its stake in shares of Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after buying an additional 2,292 shares in the last quarter. Finally, Magnetar Financial LLC acquired a new position in shares of Twist Bioscience in the first quarter valued at approximately $389,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.